MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


TOP NEWS: GSK’s Arexvy RSV vaccine approved in Japan for adults 50-59

ALN

GSK PLC said on Friday that Japan’s Ministry of Health, Labour & Welfare has approved the expansion of its Arexvy respiratory syncytial virus vaccine to include adults aged 50 to 59 who are at increased risk of severe RSV.

Previously approved in Japan in September 2023 for adults aged 60 and over, the Arexvy vaccine now targets a broader population vulnerable to RSV-related complications such as pneumonia, hospitalization, and death.

GSK, the UK‘s second-largest pharmaceutical firm, highlighted that its RSV vaccine has now been approved for use in adults aged 50-59 at increased risk in 35 countries, including the US, with additional regulatory decisions pending in other regions.

Chief Scientific Officer Tony Wood said: ‘This approval reflects our ambition to protect people at increased risk from the severe consequences of RSV infection. Adults aged 50-59 with certain underlying medical conditions can face debilitating consequences from RSV, so we are pleased to offer those in Japan a vaccine for the first time.’

The approval in Japan comes amid challenges for GSK’s blockbuster Arexvy vaccine, which saw sales drop 72% year-on-year in the third quarter to £188 million. The decline was attributed to stricter US health authority recommendations limiting its use among older and high-risk patients, coupled with a resurgence in Covid-19, which shifted vaccination priorities toward the virus over other immunizations.

Shares in GSK were up 1.1% at 1,323.50 pence each in London on Friday morning.

Copyright 2024 Alliance News Ltd. All Rights reserved.